Literature DB >> 16272179

Evidence-based guidelines for the pharmacological treatment of anxiety disorders: recommendations from the British Association for Psychopharmacology.

David S Baldwin1, Ian M Anderson, David J Nutt, Borwin Bandelow, A Bond, Jonathan R T Davidson, J A den Boer, Naomi A Fineberg, Martin Knapp, J Scott, H-U Wittchen.   

Abstract

These British Association for Psychopharmacology guidelines cover the range and aims of treatment for anxiety disorders. They are based explicitly on the available evidence and are presented as recommendations to aid clinical decision making in primary and secondary medical care. They may also serve as a source of information for patients and their carers. The recommendations are presented together with a more detailed review of the available evidence. A consensus meeting involving experts in anxiety disorders reviewed the main subject areas and considered the strength of evidence and its clinical implications. The guidelines were constructed after extensive feedback from participants and interested parties. The strength of supporting evidence for recommendations was rated. The guidelines cover the diagnosis of anxiety disorders and key steps in clinical management, including acute treatment, relapse prevention and approaches for patients who do not respond to first-line treatments.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16272179     DOI: 10.1177/0269881105059253

Source DB:  PubMed          Journal:  J Psychopharmacol        ISSN: 0269-8811            Impact factor:   4.153


  105 in total

Review 1.  A 2012 evidence-based algorithm for the pharmacotherapy for obsessive-compulsive disorder.

Authors:  Dan J Stein; Nastassja Koen; Naomi Fineberg; Leonardo F Fontenelle; Hisato Matsunaga; David Osser; H Blair Simpson
Journal:  Curr Psychiatry Rep       Date:  2012-06       Impact factor: 5.285

2.  A 2010 evidence-based algorithm for the pharmacotherapy of social anxiety disorder.

Authors:  Dan J Stein; David S Baldwin; Borwin Bandelow; Carlos Blanco; Leonardo F Fontenelle; Sing Lee; Hisato Matsunaga; David Osser; Murray B Stein; Michael van Ameringen
Journal:  Curr Psychiatry Rep       Date:  2010-10       Impact factor: 5.285

Review 3.  The use of medication in selective mutism: a systematic review.

Authors:  Katharina Manassis; Beate Oerbeck; Kristin Romvig Overgaard
Journal:  Eur Child Adolesc Psychiatry       Date:  2015-11-09       Impact factor: 4.785

4.  Association between suicide death and concordance with benzodiazepine treatment guidelines for anxiety and sleep disorders.

Authors:  Jennifer M Boggs; Richard C Lindrooth; Catherine Battaglia; Arne Beck; Debra P Ritzwoller; Brian K Ahmedani; Rebecca C Rossom; Frances L Lynch; Christine Y Lu; Beth E Waitzfelder; Ashli A Owen-Smith; Gregory E Simon; Heather D Anderson
Journal:  Gen Hosp Psychiatry       Date:  2019-11-17       Impact factor: 3.238

5.  Determination of mirtazapine in spiked human plasma and tablets by first derivative spectrofluorimetric method.

Authors:  Rasha M Youssef
Journal:  Saudi Pharm J       Date:  2010-01-06       Impact factor: 4.330

6.  Two-week treatment with the selective serotonin reuptake inhibitor citalopram reduces contextual anxiety but not cued fear in healthy volunteers: a fear-potentiated startle study.

Authors:  Christian Grillon; Chanen Chavis; Matthew F Covington; Daniel S Pine
Journal:  Neuropsychopharmacology       Date:  2008-09-17       Impact factor: 7.853

Review 7.  Current considerations in the treatment of generalized anxiety disorder.

Authors:  Martin A Katzman
Journal:  CNS Drugs       Date:  2009       Impact factor: 5.749

Review 8.  Classics in chemical neuroscience: diazepam (valium).

Authors:  Nicholas E Calcaterra; James C Barrow
Journal:  ACS Chem Neurosci       Date:  2014-02-27       Impact factor: 4.418

Review 9.  Comorbidity of anxiety and depression in children and adolescents: 20 years after.

Authors:  Colleen M Cummings; Nicole E Caporino; Philip C Kendall
Journal:  Psychol Bull       Date:  2013-11-11       Impact factor: 17.737

10.  Comorbid depression and anxiety symptoms as predictors of cardiovascular events: results from the NHLBI-sponsored Women's Ischemia Syndrome Evaluation (WISE) study.

Authors:  Thomas Rutledge; Sarah E Linke; David S Krantz; B Delia Johnson; Vera Bittner; Jo-Ann Eastwood; Wafia Eteiba; Carl J Pepine; Viola Vaccarino; Jennifer Francis; Diane A Vido; C Noel Bairey Merz
Journal:  Psychosom Med       Date:  2009-10-15       Impact factor: 4.312

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.